Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI ; volume:23 ; number:1 ; day:14 ; month:11 ; year:2023 ; pages:1-11 ; date:12.2023
Cancer imaging ; 23, Heft 1 (14.11.2023), 1-11, 12.2023
- Creator
-
Woo, Sungmin
Becker, Anton S.
Das, Jeeban P.
Ghafoor, Soleen
Arita, Yuki
Benfante, Nicole
Gangai, Natalie
Teo, Min Yuen
Goh, Alvin C.
Vargas, Hebert A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40644-023-00632-0
- URN
-
urn:nbn:de:101:1-2024013015263495967115
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Woo, Sungmin
- Becker, Anton S.
- Das, Jeeban P.
- Ghafoor, Soleen
- Arita, Yuki
- Benfante, Nicole
- Gangai, Natalie
- Teo, Min Yuen
- Goh, Alvin C.
- Vargas, Hebert A.
- SpringerLink (Online service)
Other Objects (12)
Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy
Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report
Divergent differentiation and variant morphology in invasive urothelial carcinomas – association with muscle-invasive disease
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma
Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy
Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report
Divergent differentiation and variant morphology in invasive urothelial carcinomas – association with muscle-invasive disease
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma
Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy
Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report
Divergent differentiation and variant morphology in invasive urothelial carcinomas – association with muscle-invasive disease
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon